CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero’s Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45^th Annual Health Care Conference being held in Boston, March 3^rd – 5^th, 2025. Details are as follows:

To request a meeting or for more details about the conferences please reach out to your institutional contact or email.

The webcast may also be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Connect” tab. A replay will be available on the website following the conclusion of the event.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections.
For more information, visit https://sperotherapeutics.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Inquiries: This email address is being protected from spambots. You need JavaScript enabled to view it.